$A (Agilent Technologies Inc.)

$A {{ '2016-06-15T08:34:36+0000' | timeago}} • SEC

$A repurchased about 2.4MM shares for $98MM in 1H16, which completed the repurchase under its 2013 authorization. In 2Q16, company repurchased about 2.6MM shares for $94MM under its 2015 repurchase authorization. As of April 30, $A had remaining authorization to repurchase up to $944MM of stock under this program.

$A {{ '2017-11-21T15:04:12+0000' | timeago}} • Webcast

For FY18, $A expects pharma to moderate down slightly from a 6% growth rate delivered in FY17. Agilent expects China to maintain a high-single-digit growth rate. For Europe and the chemical and energy markets, while Agilent experienced unexpectedly strong FY17 growth, the company cautiously guided to lower growth in FY18.

$A {{ '2017-11-20T21:43:30+0000' | timeago}} • Announcement

$A expects 1Q18 revenue of $1.145-1.165Bil. First-quarter non-GAAP earnings are expected to be in the range of $0.55 to $0.57 per share. For FY18, Agilent expects revenue of $4.72-4.74Bil and non-GAAP earnings of $2.50-2.56 per share.

$A {{ '2017-11-20T21:40:09+0000' | timeago}} • Announcement

With net revenue soaring 7% to $1.19Bil in 4Q17, $A posted a 40% jump in net income of $177MM or $0.54 per diluted share.

$A {{ '2017-09-22T21:43:23+0000' | timeago}} • Announcement

$A said its Dako PD-L1 IHC 22C3 pharmDx assay has an expanded label approved by the US FDA to aid in identifying gastric or GEJ adenocarcinoma patients for treatment with KEYTRUDA, an anti-PD-1 therapy manufactured by $MRK. These approvals mean these patients have the possibility of receiving a targeted anti-PD-L1 immunotherapy.

$A {{ '2017-09-20T20:44:35+0000' | timeago}} • Announcement

$A has declared a quarterly dividend of 13.2 cents per share on its common stock. The dividend will be paid on October 25, 2017, to shareholders of record on October 3, 2017.

$A {{ '2017-09-19T15:03:27+0000' | timeago}} • Announcement

$A said FDA has approved the cancer diagnostic known as PD-L1 IHC 28-8 pharmDx for use in cases of urothelial carcinoma and of squamous cell carcinoma of the head and neck. The test had previously been approved for melanoma as well as non-squamous, non-small-cell lung cancer (NSCLC).

$A {{ '2017-09-13T19:05:54+0000' | timeago}} • Announcement

$A has obtained approval from the US FDA for the GenetiSure Dx Postnatal Assay, its first comparative genomic hybridization (CGH) assay for diagnostic use. This assay enables clinical geneticists to detect genetic aberrations associated with developmental delay, intellectual disabilities and congenital irregularities more accurately.

$A {{ '2017-08-23T13:21:45+0000' | timeago}} • Announcement

Life sciences company $A filed a lawsuit against its former employees and Shanghai Echrom Electronic Technology, alleging infringement of trade secrets. The suit seeks compensation for the loss and stoppage of the use of Agilent's proprietary technologies by Shanghai Echrom and others. The employees allegedly obtained the trade secrets illegally.

$A {{ '2017-08-15T22:33:18+0000' | timeago}} • Webcast

$A expects the recently acquired Cobalt Light Systems to deliver double-digit growth. Agilent anticipates some of its ongoing chemical trials to result in commercial production in the coming years. Capex is expected to be lower in FY18 than in FY17, while the pharma business growth is seen accelerating to high-double digits in the coming quarters.

$A {{ '2017-08-15T21:58:28+0000' | timeago}} • Webcast

$A raised its outlook of operating cash flow for FY17 to $860MM from the earlier forecast of $825MM, while lowering the Capex guidance to $285MM. The free cash flow outlook has been raised by $40MM to $665MM. Attributing the strong 3Q17 results to its competitive product portfolio, Agilent said measures are afoot to expand capacity to meet demand.

$A {{ '2017-08-15T21:40:22+0000' | timeago}} • Webcast

$A said the improved performance of its pathology division showed the company is regaining market share. In 3Q17, currency had a positive impact on revenues and operating profit, of $7MM and $1M respectively. Adjusted operating margin for fiscal 2017 is expected to be 21.8%, higher by 110 basis points compared to last year.

$A {{ '2017-08-15T21:09:40+0000' | timeago}} • Infographic

$A Agilent Technologies, Inc. Earnings AlphaGraph: Q3 2017 Highlights

$A {{ '2017-08-15T20:32:02+0000' | timeago}} • Announcement

$A said it expects to record non-GAAP earnings in the range of $0.60 per share to $0.62 per share in 4Q17, on revenues of $1.15-$1.17Bil. For fiscal 2017, Agilent is looking for revenues between $4.435Bil and $4.455Bil. Full year non-GAAP earnings are forecast to be in the range of $2.29 per share to $2.31 per share.

$A {{ '2017-08-15T20:26:59+0000' | timeago}} • Announcement

Diversified technology company $A reported a 41% growth in 3Q17 profit. Earnings rose to $0.54 per share from $0.38 per share a year earlier as revenues moved up 7% to $1.1Bil. The strong growth was supported by new product launches and improved performance by all business segments. On a non-GAAP basis, earnings climbed 20% to$0.59 per share.

$A {{ '2017-08-15T20:24:30+0000' | timeago}} • Announcement

Diversified technology company $A reported a 41% growth in 3Q17 profit. Earnings rose to $0.54 per share from $0.38 per share a year earlier as revenues moved up 7% to $1.1Bil. The strong growth was supported by new product launches and improved performance by all business segments. On a non-GAAP basis, earnings climbed 20% to$0.59 per share.

$A {{ '2017-07-19T12:28:12+0000' | timeago}} • Announcement

$A has appointed Hans E Bishop to its BoD. Bishop is a co-founder and CEO of Seattle-based biopharmaceutical firm Juno Therapeutics. He has held various executive positions in the pharmaceutical industry, including as COO of Dendreon.

$A {{ '2017-07-17T17:47:21+0000' | timeago}} • Announcement

$A introduced a new sequencing library prep solution, Agilent SureSelectXTHS. SureSelectXTHS is a streamlined, high-sensitivity solution for research, optimized for labs with a requirement to sequence DNA from formalin-fixed paraffin-embedded (FFPE) samples, which may have degraded over time.

$A {{ '2017-07-07T15:46:38+0000' | timeago}} • Announcement

Analytical laboratory technology provider $A has acquired UK-based Cobalt Light Systems, a provider of Raman spectroscopic instruments, for GBP 40MM in cash. After completion of the deal, Cobalt’s CEO will remain with Agilent as Director of Raman Spectroscopy. Agilent’s global center for Raman spectroscopy will be Oxford.

$A {{ '2017-06-06T18:09:45+0000' | timeago}} • Announcement

$A has launched a high-resolution, accurate-mass system designed for laboratories engaged in food and environmental testing, life science research, forensics and chemical analysis. The system allows scientists to employ analytical techniques that were not previously practical and facilitate greater exploration of unknown chemical samples.

$A {{ '2017-06-02T16:05:23+0000' | timeago}} • Announcement

$A and Agendia Inc. agreed to expand their relationship to include the development of an RNA-Seq kit version of Agendia's currently marketed MammaPrint and BluePrint tests. The agreement accelerates the development of tests to help assess risk of disease recurrence in women with early-stage breast cancer.

Recent Transcripts

JBL (Jabil Circuit Inc.)
Thursday, December 14 2017 - 9:30pm
MEI (Methode Electronics, Inc.)
Thursday, December 7 2017 - 4:00pm
IEC (IEC Electronics Corp.)
Wednesday, December 6 2017 - 3:00pm
MRVL (Marvell Technology Group Ltd.)
Tuesday, November 28 2017 - 9:45pm
A (Agilent Technologies Inc.)
Monday, November 20 2017 - 9:30pm
AIRI (Air Industries Group)
Thursday, November 16 2017 - 1:30pm
NVDA (NVIDIA Corporation)
Thursday, November 9 2017 - 10:00pm
CVU (CPI Aerostructures Inc.)
Wednesday, November 8 2017 - 1:30pm
VPG (Vishay Precision Group, Inc.)
Tuesday, November 7 2017 - 3:00pm
QGEN (Qiagen NV)
Tuesday, November 7 2017 - 2:00pm
MCHP (Microchip Technology Inc.)
Monday, November 6 2017 - 10:00pm
INTT (inTEST Corp.)
Thursday, November 2 2017 - 9:00pm
KEM (KEMET Corp.)
Thursday, November 2 2017 - 1:00pm
COMM (CommScope Holding Company, Inc.)
Wednesday, November 1 2017 - 12:30pm
LBY (Libbey Inc.)
Tuesday, October 31 2017 - 3:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, October 26 2017 - 2:30pm
TER (Teradyne Inc.)
Thursday, October 26 2017 - 2:00pm
VSH (Vishay Intertechnology Inc.)
Thursday, October 26 2017 - 1:00pm
F (Ford Motor Co.)
Thursday, October 26 2017 - 1:00pm
XLNX (Xilinx Inc.)
Wednesday, October 25 2017 - 9:00pm

AlphaGraphics you may like